Adamas Pharmaceuticals (ADMS) PT Lowered to $23 at Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Price: $8.22 --0%
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 22 | New: 16
Rating Summary:
4 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 22 | New: 16
Join SI Premium – FREE
Piper Jaffray analyst David Amsellem lowered the price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $23.00 (from $49.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- HSBC Upgrades FedEx (FDX) to Buy
- Vertiv (VRT) PT Raised to $376 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
